MO996: Immunogenicity Rates After Sars-Cov-2 Vaccination Among Kidney Transplant Recipients: A Meta-Analysis

Abstract

Abstract BACKGROUND AND AIMS Various COVID-19 vaccines have been developed across a range of platforms and have been deployed among immunocompetent individuals, but data have been lacking regarding the effects of these vaccines among kidney transplant recipients. While it is true that there is high immunogenicity after COVID vaccination among immunocompetent individuals, disappointing results in the humoral response were seen among kidney transplant recipients. There are studies that undermine the over-all immunogenicity among end-stage renal disease on renal replacement therapy, but little is known regarding data among kidney transplant recipients. Hence, this meta-analysis would like to investigate the over-all immunogenicity rate among kidney transplant recipient after COVID vaccination. METHOD A systematic search of relevant articles was performed on two English databases (Pubmed, Cochrane Library) published between January 2020 to November 2021 and we included studies on kidney transplant recipient who reported on antibody response rate after COVID vaccination. RESULTS Thirteen studies were included in this meta-analysis with a total of 2231 participants, analyzing immunogenicity rates among kidney transplant recipients towards the following vaccines: [mRNA-1273 SARS-CoV-2 Vaccine (Moderna), Inactivated whole-virus SARS-CoV-2 vaccine, CoronaVac® (Sinovac), mRNA BNT162b2 vaccine (Pfizer-BioNTech), and Oxford–AstraZeneca COVID-19]. The over-all immunogenicity rate among kidney transplant recipient was 43% (95% CI: 36–52%) with I2 = 80%. Compared with controls, kidney transplant recipient had a 53% reduced likelihood of attaining seroconversion after a standard 2 doses of COVID vaccine (RR: 0.47, 95% CI: 0.34–0.65). CONCLUSION The overall immunogenicity among Kidney Transplant (KT) recipient was 43% and compared with transplant-naïve group, KT recipients have a 53% reduced likelihood of attaining seroconversion. Moreover, KT recipients whom had prior COVID-19 infection, and received mRNA-1273 COVID-19 Vaccine (Moderna) as their COVID vaccine has higher antibody response rate. The addition of booster dose of vaccine showed a slight increase in immunogenicity compared with those whom had two doses only. Lastly, old age and high levels of anti-metabolite might have cause low level of immunogenicity among kidney transplant recipient after COVID vaccination.